Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma
Abstract
:1. Introduction
2. Results
2.1. MIA-690 Increases the Inhibitory Effects of Cisplatin/Pemetrexed on Cell Viability of PM Cells
2.2. MIA-690 Potentiates the In Vivo Antitumor Effect of Cisplatin/Pemetrexed in PM Xenografts
2.3. The Combination of MIA-690 with Cisplatin and Pemetrexed Is More Effective than Chemotherapeutic Drugs Alone on the Inhibition of Proliferative and Survival Pathways
2.4. MIA-690 Increases the Anti-inflammatory Action of Cisplatin and Pemetrexed in PM Tumors
2.5. MIA-690 Potentiates the Effect of Cisplatin/Pemetrexed on Inhibition of VEGF and IGF-1 Expression in PM Tumors
3. Discussion
4. Materials and Methods
4.1. Reagents
4.2. Cell Culture
4.3. Cell Survival and Proliferation
4.4. Caspase-3 Activity
4.5. Combination Studies
4.6. In Vivo Tumor Growth
4.7. Histochemistry
4.8. Western Blot Analysis
4.9. Real-Time PCR
4.10. IGF-1 Analysis
4.11. Statistical Analysis
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Yap, T.A.; Aerts, J.G.; Popat, S.; Fennell, D.A. Novel insights into mesothelioma biology and implications for therapy. Nat. Rev. Cancer 2017, 17, 475–488. [Google Scholar] [CrossRef] [PubMed]
- Kuryk, L.; Rodella, G.; Staniszewska, M.; Pancer, K.W.; Wieczorek, M.; Salmaso, S.; Caliceti, P.; Garofalo, M. Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects. Front. Oncol. 2022, 12, 916839. [Google Scholar] [CrossRef]
- Sauter, J.L.; Dacic, S.; Galateau-Salle, F.; Attanoos, R.L.; Butnor, K.J.; Churg, A.; Husain, A.N.; Kadota, K.; Khoor, A.; Nicholson, A.G.; et al. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. J. Thorac. Oncol. 2022, 17, 608–622. [Google Scholar] [CrossRef]
- Obacz, J.; Yung, H.; Shamseddin, M.; Linnane, E.; Liu, X.; Azad, A.A.; Rassl, D.M.; Fairen-Jimenez, D.; Rintoul, R.C.; Nikolic, M.Z.; et al. Biological basis for novel mesothelioma therapies. Br. J. Cancer 2021, 125, 1039–1055. [Google Scholar] [CrossRef]
- Vogelzang, N.J.; Rusthoven, J.J.; Symanowski, J.; Denham, C.; Kaukel, E.; Ruffie, P.; Gatzemeier, U.; Boyer, M.; Emri, S.; Manegold, C.; et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003, 21, 2636–2644. [Google Scholar] [CrossRef]
- Tsao, A.S.; Pass, H.I.; Rimner, A.; Mansfield, A.S. New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options. J. Clin. Oncol. 2022, 40, 681–692. [Google Scholar] [CrossRef] [PubMed]
- Mujoomdar, A.A.; Tilleman, T.R.; Richards, W.G.; Bueno, R.; Sugarbaker, D.J. Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: Result in a cohort of 203 resection specimens. J. Thorac. Cardiovasc. Surg. 2010, 140, 352–355. [Google Scholar] [CrossRef]
- Zalcman, G.; Mazieres, J.; Margery, J.; Greillier, L.; Audigier-Valette, C.; Moro-Sibilot, D.; Molinier, O.; Corre, R.; Monnet, I.; Gounant, V.; et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet 2016, 387, 1405–1414. [Google Scholar] [CrossRef]
- Lapidot, M.; Saladi, S.V.; Salgia, R.; Sattler, M. Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma. Front. Pharmacol. 2021, 12, 806570. [Google Scholar] [CrossRef] [PubMed]
- Guillemin, R.; Brazeau, P.; Bohlen, P.; Esch, F.; Ling, N.; Wehrenberg, W.B. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982, 218, 585–587. [Google Scholar] [CrossRef] [PubMed]
- Granata, R. Peripheral activities of growth hormone-releasing hormone. J. Endocrinol. Investig. 2016, 39, 721–727. [Google Scholar] [CrossRef]
- Schally, A.V.; Zhang, X.; Cai, R.; Hare, J.M.; Granata, R.; Bartoli, M. Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists. Endocrinology 2019, 160, 1600–1612. [Google Scholar] [CrossRef]
- Cai, R.; Schally, A.V.; Cui, T.; Szalontay, L.; Halmos, G.; Sha, W.; Kovacs, M.; Jaszberenyi, M.; He, J.; Rick, F.G.; et al. Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities. Peptides 2014, 52, 104–112. [Google Scholar] [CrossRef]
- Granata, R.; Trovato, L.; Gallo, M.P.; Destefanis, S.; Settanni, F.; Scarlatti, F.; Brero, A.; Ramella, R.; Volante, M.; Isgaard, J.; et al. Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart. Cardiovasc. Res. 2009, 83, 303–312. [Google Scholar] [CrossRef]
- Kanashiro-Takeuchi, R.M.; Tziomalos, K.; Takeuchi, L.M.; Treuer, A.V.; Lamirault, G.; Dulce, R.; Hurtado, M.; Song, Y.; Block, N.L.; Rick, F.; et al. Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc. Natl. Acad. Sci. USA 2010, 107, 2604–2609. [Google Scholar] [CrossRef]
- Recinella, L.; Chiavaroli, A.; Orlando, G.; Ferrante, C.; Marconi, G.D.; Gesmundo, I.; Granata, R.; Cai, R.; Sha, W.; Schally, A.V.; et al. Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice. Sci. Rep. 2020, 10, 732. [Google Scholar] [CrossRef]
- Zhang, X.; Cui, T.; He, J.; Wang, H.; Cai, R.; Popovics, P.; Vidaurre, I.; Sha, W.; Schmid, J.; Ludwig, B.; et al. Beneficial effects of growth hormone-releasing hormone agonists on rat INS-1 cells and on streptozotocin-induced NOD/SCID mice. Proc. Natl. Acad. Sci. USA 2015, 112, 13651–13656. [Google Scholar] [CrossRef]
- Kiaris, H.; Chatzistamou, I.; Papavassiliou, A.G.; Schally, A.V. Growth hormone-releasing hormone: Not only a neurohormone. Trends Endocrinol. Metab. TEM 2011, 22, 311–317. [Google Scholar] [CrossRef]
- Schally, A.V.; Varga, J.L.; Engel, J.B. Antagonists of growth-hormone-releasing hormone: An emerging new therapy for cancer. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4, 33–43. [Google Scholar] [CrossRef]
- Sato, K.; Hotta, M.; Kageyama, J.; Hu, H.Y.; Dong, M.H.; Ling, N. Synthetic analogs of growth hormone-releasing factor with antagonistic activity in vitro. Biochem. Biophys. Res. Commun. 1990, 167, 360–366. [Google Scholar] [CrossRef]
- Zarandi, M.; Cai, R.; Kovacs, M.; Popovics, P.; Szalontay, L.; Cui, T.; Sha, W.; Jaszberenyi, M.; Varga, J.; Zhang, X.; et al. Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth. Peptides 2017, 89, 60–70. [Google Scholar] [CrossRef] [PubMed]
- Cai, R.; Zhang, X.; Wang, H.; Cui, T.; Halmos, G.; Sha, W.; He, J.; Popovics, P.; Vidaurre, I.; Zhang, C.; et al. Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity. Peptides 2022, 150, 170716. [Google Scholar] [CrossRef] [PubMed]
- Recinella, L.; Chiavaroli, A.; Veschi, S.; Di Valerio, V.; Lattanzio, R.; Orlando, G.; Ferrante, C.; Gesmundo, I.; Granata, R.; Cai, R.; et al. Antagonist of growth hormone-releasing hormone MIA-690 attenuates the progression and inhibits growth of colorectal cancer in mice. Biomed. Pharmacother. 2022, 146, 112554. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.; Zhang, X.; Vidaurre, I.; Cai, R.; Sha, W.; Schally, A.V. Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone. Int. J. Cancer 2018, 142, 2394–2404. [Google Scholar] [CrossRef] [PubMed]
- Gan, J.; Ke, X.; Jiang, J.; Dong, H.; Yao, Z.; Lin, Y.; Lin, W.; Wu, X.; Yan, S.; Zhuang, Y.; et al. Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3/NF-kappaB signaling. Proc. Natl. Acad. Sci. USA 2016, 113, 14745–14750. [Google Scholar] [CrossRef]
- Zhang, C.; Cui, T.; Cai, R.; Wangpaichitr, M.; Mirsaeidi, M.; Schally, A.V.; Jackson, R.M. Growth Hormone-Releasing Hormone in Lung Physiology and Pulmonary Disease. Cells 2020, 9, 2331. [Google Scholar] [CrossRef] [PubMed]
- Zhang, C.; Cai, R.; Lazerson, A.; Delcroix, G.; Wangpaichitr, M.; Mirsaeidi, M.; Griswold, A.J.; Schally, A.V.; Jackson, R.M. Growth Hormone-Releasing Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis due to Bleomycin. Lung 2019, 197, 541–549. [Google Scholar] [CrossRef]
- Zhang, C.; Tian, R.; Dreifus, E.M.; Hashemi Shahraki, A.; Holt, G.; Cai, R.; Griswold, A.; Bejarano, P.; Jackson, R.; A, V.S.; et al. Activity of the growth hormone-releasing hormone antagonist MIA602 and its underlying mechanisms of action in sarcoidosis-like granuloma. Clin. Transl. Immunol. 2021, 10, e1310. [Google Scholar] [CrossRef]
- Villanova, T.; Gesmundo, I.; Audrito, V.; Vitale, N.; Silvagno, F.; Musuraca, C.; Righi, L.; Libener, R.; Riganti, C.; Bironzo, P.; et al. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. Proc. Natl. Acad. Sci. USA 2019, 116, 2226–2231. [Google Scholar] [CrossRef] [PubMed]
- Arulananda, S.; O’Brien, M.; Evangelista, M.; Jenkins, L.J.; Poh, A.R.; Walkiewicz, M.; Leong, T.; Mariadason, J.M.; Cebon, J.; Balachander, S.B.; et al. A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. Cell Death Discov. 2021, 7, 122. [Google Scholar] [CrossRef]
- Cho, H.; Matsumoto, S.; Fujita, Y.; Kuroda, A.; Menju, T.; Sonobe, M.; Kondo, N.; Torii, I.; Nakano, T.; Lara, P.N.; et al. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma. J. Thorac. Oncol. 2017, 12, 477–490. [Google Scholar] [CrossRef] [PubMed]
- Engeland, K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022, 29, 946–960. [Google Scholar] [CrossRef] [PubMed]
- Saini, S.S.; Klein, M.A. Targeting cyclin D1 in non-small cell lung cancer and mesothelioma cells by antisense oligonucleotides. Anticancer. Res. 2011, 31, 3683–3690. [Google Scholar] [PubMed]
- Romagnoli, S.; Fasoli, E.; Vaira, V.; Falleni, M.; Pellegrini, C.; Catania, A.; Roncalli, M.; Marchetti, A.; Santambrogio, L.; Coggi, G.; et al. Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis. Am. J. Pathol. 2009, 174, 762–770. [Google Scholar] [CrossRef] [PubMed]
- Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature 2008, 454, 436–444. [Google Scholar] [CrossRef]
- Canino, C.; Luo, Y.; Marcato, P.; Blandino, G.; Pass, H.I.; Cioce, M. A STAT3-NFkB/DDIT3/CEBPbeta axis modulates ALDH1A3 expression in chemoresistant cell subpopulations. Oncotarget 2015, 6, 12637–12653. [Google Scholar] [CrossRef]
- Rick, F.G.; Seitz, S.; Schally, A.V.; Szalontay, L.; Krishan, A.; Datz, C.; Stadlmayr, A.; Buchholz, S.; Block, N.L.; Hohla, F. GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. Cell Cycle 2012, 11, 4203–4210. [Google Scholar] [CrossRef]
- Seitz, S.; Rick, F.G.; Schally, A.V.; Treszl, A.; Hohla, F.; Szalontay, L.; Zarandi, M.; Ortmann, O.; Engel, J.B.; Buchholz, S. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers. Oncol. Rep. 2013, 30, 413–418. [Google Scholar] [CrossRef]
- Schally, A.V.; Perez, R.; Block, N.L.; Rick, F.G. Potentiating effects of GHRH analogs on the response to chemotherapy. Cell Cycle 2015, 14, 699–704. [Google Scholar] [CrossRef]
- Hohla, F.; Schally, A.V.; Szepeshazi, K.; Varga, J.L.; Buchholz, S.; Koster, F.; Heinrich, E.; Halmos, G.; Rick, F.G.; Kannadka, C.; et al. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proc. Natl. Acad. Sci. USA 2006, 103, 14513–14518. [Google Scholar] [CrossRef] [Green Version]
- Malakoti, F.; Targhazeh, N.; Abadifard, E.; Zarezadeh, R.; Samemaleki, S.; Asemi, Z.; Younesi, S.; Mohammadnejad, R.; Hadi Hossini, S.; Karimian, A.; et al. DNA repair and damage pathways in mesothelioma development and therapy. Cancer Cell Int. 2022, 22, 176. [Google Scholar] [CrossRef] [PubMed]
- Rick, F.G.; Schally, A.V.; Szalontay, L.; Block, N.L.; Szepeshazi, K.; Nadji, M.; Zarandi, M.; Hohla, F.; Buchholz, S.; Seitz, S. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc. Natl. Acad. Sci. USA 2012, 109, 1655–1660. [Google Scholar] [CrossRef] [PubMed]
- Marques, M.; Tranchant, R.; Risa-Ebri, B.; Suarez-Solis, M.L.; Fernandez, L.C.; Carrillo-de-Santa-Pau, E.; Del Pozo, N.; Martinez de Villarreal, J.; Meiller, C.; Allory, Y.; et al. Combined MEK and PI3K/p110beta Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features. Cancer Res. 2020, 80, 843–856. [Google Scholar] [CrossRef] [PubMed]
- Gesmundo, I.; Granato, G.; Fuentes-Fayos, A.C.; Alvarez, C.V.; Dieguez, C.; Zatelli, M.C.; Congiusta, N.; Banfi, D.; Prencipe, N.; Leone, S.; et al. Antagonists of Growth Hormone-Releasing Hormone Inhibit the Growth of Pituitary Adenoma Cells by Hampering Oncogenic Pathways and Promoting Apoptotic Signaling. Cancers 2021, 13, 3950. [Google Scholar] [CrossRef] [PubMed]
- Barabutis, N.; Siejka, A.; Schally, A.V. Growth hormone releasing hormone induces the expression of nitric oxide synthase. J. Cell Mol. Med. 2011, 15, 1148–1155. [Google Scholar] [CrossRef]
- Barabutis, N.; Siejka, A. The highly interrelated GHRH, p53, and Hsp90 universe. Cell Biol. Int. 2020, 44, 1558–1563. [Google Scholar] [CrossRef]
- Volakaki, A.A.; Lafkas, D.; Kassi, E.; Schally, A.V.; Papavassiliou, A.G.; Kiaris, H. Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132. J. Mol. Endocrinol. 2008, 41, 389–392. [Google Scholar] [CrossRef]
- Hohla, F.; Buchholz, S.; Schally, A.V.; Seitz, S.; Rick, F.G.; Szalontay, L.; Varga, J.L.; Zarandi, M.; Halmos, G.; Vidaurre, I.; et al. GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle 2009, 8, 3149–3156. [Google Scholar] [CrossRef]
- Uxa, S.; Castillo-Binder, P.; Kohler, R.; Stangner, K.; Muller, G.A.; Engeland, K. Ki-67 gene expression. Cell Death Differ. 2021, 28, 3357–3370. [Google Scholar] [CrossRef]
- Perez-Roger, I.; Kim, S.H.; Griffiths, B.; Sewing, A.; Land, H. Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J. 1999, 18, 5310–5320. [Google Scholar] [CrossRef] [Green Version]
- Choi, Y.J.; Anders, L. Signaling through cyclin D-dependent kinases. Oncogene 2014, 33, 1890–1903. [Google Scholar] [CrossRef] [PubMed]
- Ramael, M.; Van den Bossche, J.; Buysse, C.; Deblier, I.; Segers, K.; Van Marck, E. Immunoreactivity for c-fos and c-myc protein with the monoclonal antibodies 14E10 and 6E10 in malignant mesothelioma and non-neoplastic mesothelium of the pleura. Histol. Histopathol. 1995, 10, 639–643. [Google Scholar] [PubMed]
- Riquelme, E.; Suraokar, M.B.; Rodriguez, J.; Mino, B.; Lin, H.Y.; Rice, D.C.; Tsao, A.; Wistuba, I.I. Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma. J. Thorac. Oncol. 2014, 9, 998–1007. [Google Scholar] [CrossRef]
- Tan, Y.; Sementino, E.; Chernoff, J.; Testa, J.R. Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity. Am. J. Cancer Res. 2017, 7, 1724–1737. [Google Scholar] [PubMed]
- Dhanasekaran, R.; Deutzmann, A.; Mahauad-Fernandez, W.D.; Hansen, A.S.; Gouw, A.M.; Felsher, D.W. The MYC oncogene-the grand orchestrator of cancer growth and immune evasion. Nat. Rev. Clin. Oncol. 2022, 19, 23–36. [Google Scholar] [CrossRef] [PubMed]
- Cioce, M.; Canino, C.; Pulito, C.; Muti, P.; Strano, S.; Blandino, G. Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells. Cell Cycle 2012, 11, 132–140. [Google Scholar] [CrossRef]
- Rick, F.G.; Schally, A.V.; Block, N.L.; Nadji, M.; Szepeshazi, K.; Zarandi, M.; Vidaurre, I.; Perez, R.; Halmos, G.; Szalontay, L. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc. Natl. Acad. Sci. USA 2011, 108, 3755–3760. [Google Scholar] [CrossRef]
- Barabutis, N.; Schally, A.V.; Siejka, A. P53, GHRH, inflammation and cancer. EBioMedicine 2018, 37, 557–562. [Google Scholar] [CrossRef]
- Fukumura, D.; Kashiwagi, S.; Jain, R.K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 2006, 6, 521–534. [Google Scholar] [CrossRef]
- Nuvoli, B.; Galati, R. Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma. Mol. Cancer Ther. 2013, 12, 844–852. [Google Scholar] [CrossRef] [Green Version]
- Soini, Y.; Kahlos, K.; Puhakka, A.; Lakari, E.; Saily, M.; Paakko, P.; Kinnula, V. Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma. Br. J. Cancer 2000, 83, 880–886. [Google Scholar] [CrossRef] [PubMed]
- Recinella, L.; Chiavaroli, A.; Di Valerio, V.; Veschi, S.; Orlando, G.; Ferrante, C.; Gesmundo, I.; Granata, R.; Cai, R.; Sha, W.; et al. Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice. Sci. Rep. 2021, 11, 2530. [Google Scholar] [CrossRef] [PubMed]
- Strbac, D.; Dolzan, V. Matrix Metalloproteinases as Biomarkers and Treatment Targets in Mesothelioma: A Systematic Review. Biomolecules 2021, 11, 1272. [Google Scholar] [CrossRef]
- Yang, H.; Rivera, Z.; Jube, S.; Nasu, M.; Bertino, P.; Goparaju, C.; Franzoso, G.; Lotze, M.T.; Krausz, T.; Pass, H.I.; et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc. Natl. Acad. Sci. USA 2010, 107, 12611–12616. [Google Scholar] [CrossRef] [PubMed]
- Xue, J.; Patergnani, S.; Giorgi, C.; Suarez, J.; Goto, K.; Bononi, A.; Tanji, M.; Novelli, F.; Pastorino, S.; Xu, R.; et al. Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy. Proc. Natl. Acad. Sci. USA 2020, 117, 25543–25552. [Google Scholar] [CrossRef]
- Munoz-Moreno, L.; Schally, A.V.; Prieto, J.C.; Carmena, M.J.; Bajo, A.M. Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer. Prostate 2018, 78, 915–926. [Google Scholar] [CrossRef]
- Siejka, A.; Barabutis, N.; Schally, A.V. GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro. Peptides 2012, 37, 63–68. [Google Scholar] [CrossRef]
- Hoang, C.D.; Zhang, X.; Scott, P.D.; Guillaume, T.J.; Maddaus, M.A.; Yee, D.; Kratzke, R.A. Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: Association with distinct malignant phenotypes. Cancer Res. 2004, 64, 7479–7485. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gesmundo, I.; Pedrolli, F.; Vitale, N.; Bertoldo, A.; Orlando, G.; Banfi, D.; Granato, G.; Kasarla, R.; Balzola, F.; Deaglio, S.; et al. Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma. Int. J. Mol. Sci. 2022, 23, 11248. https://doi.org/10.3390/ijms231911248
Gesmundo I, Pedrolli F, Vitale N, Bertoldo A, Orlando G, Banfi D, Granato G, Kasarla R, Balzola F, Deaglio S, et al. Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma. International Journal of Molecular Sciences. 2022; 23(19):11248. https://doi.org/10.3390/ijms231911248
Chicago/Turabian StyleGesmundo, Iacopo, Francesca Pedrolli, Nicoletta Vitale, Alessia Bertoldo, Giulia Orlando, Dana Banfi, Giuseppina Granato, Ramesh Kasarla, Federico Balzola, Silvia Deaglio, and et al. 2022. "Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma" International Journal of Molecular Sciences 23, no. 19: 11248. https://doi.org/10.3390/ijms231911248